INSM regulatory event: a negative outcome, -6.6%

On June 24, 2016, 280 mg Arikayce™ — Insmed Incorporated (Bronchiectasis) reached its regulatory event. The result was a negative outcome, and the stock moved -6.6% in the window around the event. It had already run -18.6% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.